### Top Altcoins with Long-Term Potential in 2025
Cryptocurrencies remain highly volatile, and while Bitcoin often dominates discussions, altcoins (alternative coins) offer diverse opportunities in areas like decentralized finance (DeFi), scalability, and real-world utility. Based on analyses from financial experts and market observers as of September 2025, several altcoins stand out for their technological foundations, adoption trends, and growth projections. These selections focus on coins with strong ecosystems, ongoing development, and potential for mainstream integration. Remember, this is not financial advice—always conduct your own research and consider market risks.
I've compiled a list of 8 promising altcoins, drawing from recurring recommendations across sources. They're ranked loosely by market cap and mentions frequency, with brief explanations of their long-term appeal.
| Altcoin | Key Strengths and Long-Term Potential | Projected Insights (2025-2030) |
|---------|--------------------------------------|--------------------------------|
| Ethereum (ETH) | As the leading smart contract platform, Ethereum benefits from upgrades like sharding for better scalability and its dominance in DeFi and NFTs. It's seen as a foundational layer for Web3. | Price forecasts range from $1,666 to over $6,000 in 2025, with potential for $10,000+ long-term due to institutional adoption. |
| Solana (SOL) | Known for high-speed transactions and low fees, Solana is gaining traction in gaming, DeFi, and meme coins. Its ecosystem is expanding rapidly despite past outages. | Could reach $200-$500 by 2025, with long-term growth tied to mobile and enterprise integrations. |
| Ripple (XRP) | Focuses on cross-border payments with partnerships in banking. Regulatory clarity post-SEC lawsuit has boosted confidence. | Targets $1-$3 in 2025, potentially higher with global remittance adoption. |
| Chainlink (LINK) | Provides oracle services for secure data feeds to smart contracts, essential for DeFi and real-world applications like insurance. | Forecasts suggest $20-$50 by 2025, driven by increasing blockchain interconnectivity. |
| Binance Coin (BNB) | Powers the Binance ecosystem, including trading fee discounts and DeFi on BNB Chain. Strong utility in one of the largest exchanges. | Could hit $600-$1,000 in 2025, with growth from exchange expansions and regulatory compliance. |
| Avalanche (AVAX) | Offers fast, eco-friendly transactions with subnet capabilities for custom blockchains. Popular in gaming and institutional finance. | Projections: $50-$150 by 2025, bolstered by partnerships and scalability focus. |
| Hedera (HBAR) | Enterprise-grade blockchain with high throughput and low costs, used in supply chain and payments. Backed by major corporations like Google and IBM. | Potential to reach $0.20-$0.50 in 2025, with long-term upside from real-world enterprise adoption. |
| Polkadot (DOT) | Enables interoperability between blockchains via parachains. Strong for cross-chain DeFi and data sharing. | Estimates: $10-$30 by 2025, growing with multichain ecosystem developments. |
Other notable mentions include Polygon (MATIC) for Ethereum scaling, Uniswap (UNI) for decentralized exchanges, and emerging ones like Sui (SUI) for high-performance apps. Factors like regulatory changes, technological upgrades (e.g., Ethereum's Dencun upgrade), and macroeconomic trends (e.g., interest rates) will influence outcomes. For the latest market data, check exchanges like Binance or Coinbase. Invest wisely!
Sunday, September 14, 2025
Top Altcoins with Long-Term Potential in 2025 - Grok AI
Shares - ASX
Propel Funeral Partners Ltd (ASX: PFP)
Propel is the second largest funeral operator in Australia and New Zealand. As morbid as it sounds, I think there are three key reasons to like the business.
Firstly, I'd say it has very defensive earnings. Sadly, there is a certain volume of funerals that occur each year. Plus, the price of funerals is generally rising alongside inflation, so the company has a solid organic tailwind for its top line and bottom line.
The main reason why I think it's a great long-term buy is the fact that it's exposed to the tailwind of rising projected deaths. Propel says that death volumes are expected to increase by 2.8% per year between 2025 to 2035 and then grow by another 2.4% per year between 2036 to 2045. While there may be slight variances to the growth rate some years, there are clear tailwinds for the business.
Over the long-term, I'm expecting the ASX share's operating profit margins to rise over time thanks to operating leverage.
Altcoins / Cryptos with Good Long-Term Potential - Chat GPT
✅ Altcoins / Cryptos with Good Long-Term Potential
These are ones people are talking about as having strong fundamentals, developer activity, and use cases:
| Coin | Why It’s Seen as Strong | Things to Watch / Risks |
|---|---|---|
| Ethereum (ETH) | Most mature smart contract platform; upcoming upgrades make staking and L2 / scaling more efficient; widely used in DeFi, NFTs, etc. (coinpush.app) | Gas fees, competition from other L1s/L2s; regulatory risks; scaling delays. |
| Bitcoin (BTC) | Store of value; very high liquidity; considered "digital gold.” Strong institutional interest. (Coinpaper) | Volatility; opportunity cost; doesn’t have smart contract utility. |
| Solana (SOL) | High throughput, strong developer ecosystem; fast transaction speed; lots of projects building on it. (coinpush.app) | Network outages historically; competition; risk of centralization. |
| Cardano (ADA) | Research-driven, peer reviewed development; strong focus on sustainability, scalability, and utility among emerging markets. (coinpush.app) | Slower development/feature rollout; sometimes criticised for lagging in DeFi / dApp adoption vs peers. |
| Polkadot (DOT) | Interoperability, parachain model, cross-chain communication, flexibility for projects to build with shared security. (coinpush.app) | Complexity; competition from other cross-chain protocols; governance risk. |
| Chainlink (LINK) | Oracles are essential in DeFi; LINK provides data to many smart contracts; strong track record. (coinpush.app) | Reliance on external ecosystem demand; regulatory scrutiny of data usage. |
| XRP (Ripple) | Fast cross-border settlement use case; continuing legal clarity (in some jurisdictions) improving. (Cryptonews) | Legal/regulatory risk (Ripple has been in court in US for a long time); adoption may be slower. |
⚠️ Risks to Keep in Mind
-
Crypto markets are volatile. Even strong fundamentals don’t protect from big swings.
-
Regulatory risk is growing globally (DeFi, token classifications, securities laws).
-
Network outages, security flaws, or bugs in consensus or smart contracts could hit some coins harder.
-
Competition is intense; newer chains, layer-2s, zero-knowledge (ZK) solutions are gaining.
Monday, August 25, 2025
Crypto Monthly update : Noteworthy Cryptocurrencies for Short- to Mid-Term Holding
| Cryptocurrency | Key Appeal | Degree of Risk | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ethereum (ETH) | Institutional appeal, ETF optimism | Medium | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Solana (SOL) | Scalability, developer ecosystem | Medium | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cardano (ADA) | Strong fundamentals, long-term potential | Medium-Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chainlink (LINK) | Core DeFi infrastructure | Medium | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diversified Crypto Portfolio Breakdown |
Thursday, July 31, 2025
DRUG - Betashares Global Healthcare Currency Hedged ETF
Why the Betashares Global Healthcare ETF – Currency-Hedged (ASX: DRUG) has slipped in 2025
| Factor | What’s happening | Evidence |
|---|---|---|
| 1. Under-performing global healthcare stocks | The sector has lagged broad equity benchmarks this year (-0.6 % YTD vs the S&P 500’s +8 %). Big-pharma names such as Pfizer, Johnson & Johnson and Roche – together almost half of DRUG’s portfolio – have been pressured by drug-price politics, looming patent-cliffs and faltering obesity-drug pipelines. | Bloomberg sector table (Bloomberg.com); FT coverage of drug-price crackdown & patent-cliff worries (Financial Times, Financial Times) |
| 2. Currency-hedging drag | DRUG hedges USD, EUR, CHF etc. back to AUD. With the Aussie dollar up ~5 % YTD vs USD the hedge has worked (it shielded you from a stronger AUD), but it incurred a carry cost because US cash rates (≈ 5 ½ %) are still above Aussie rates (≈ 4 ¼ %). That negative “forward-points” cost is taken out of fund returns each day. | AUD spot +5.22 % YTD (Bloomberg.com); hedging mechanics in Betashares factsheet (uses daily forwards) (Betashares) |
| 3. Large mid-year distribution | On 1 July 2024 the fund went ex-distribution for A$0.223 per unit and again (smaller) on 2 Jan 2025. Price charts that ignore reinvested cash make the drop look steeper than the total-return reality. | Distribution history table (Market Index) |
| 4. Higher fees than peers | At 0.57 % p.a. DRUG’s management cost is > IXJ (0.43 %) or VHT (0.47 %). In a flat market fees bite more. | Key-facts section (Betashares) |
Taken together, these explain why the unit price has slipped from A$8.81 (30 Jun 2024 close) to A$7.47 NAV (31 Jul 2025) – roughly -15 % on price, or -12 % total-return after adding back cash payouts. (Market Index)
Is it a good entry point?
| Lens | What it tells us now |
|---|---|
| Valuation | MSCI World Healthcare forward P/E ≈ 15.9× vs its 10-yr average ~18× – the sector is not “cheap”, but it has de-rated to a post-COVID low. (MSCI) |
| Macro backdrop | Healthcare is defensive, yet 2025 rate-cut hopes have pushed investors back into cyclicals and tech. A US election season with heavy drug-price rhetoric could keep a lid on multiples until November. |
| Currency view | If you expect the AUD to stay firm or rise, the hedged class limits FX noise. If you think the AUD could fall back below US $0.65, the un-hedged IXJ ETF may rebound faster. |
| Sector catalysts | • US FDA decisions on GLP-1 obesity drugs (benefits Lilly/Novo, hurts others). • M&A pick-up as big-pharma reloads pipelines before 2028 patent cliffs. • Possible easing of US drug-price rhetoric after the election. |
Bottom line
Pros
-
Diversified exposure to >100 global healthcare giants in a single ASX trade.
-
Currency hedge shelters you from AUD swings.
-
Sector trading at a discount to its own 10-year average.
Cons
-
Negative hedge carry (~0.6-0.8 % p.a.) plus 0.57 % fee.
-
Political overhang on drug pricing could extend through the US election.
-
Portfolio heavily concentrated in mega-cap pharma that are currently out of favour.
Long-term investors (3-5 yr horizon): a reasonable accumulation point if you want defensive, ageing-population exposure and prefer to keep currency risk minimal. Dollar-cost-averaging can soften further volatility.
Tactical traders (6-12 mo): momentum remains weak (Investing.com technical signal = “Strong Sell”) (Investing.com Australia); waiting for a clear price base, or buying the un-hedged IXJ if you expect AUD weakness, may offer better risk/reward.
(Always consider your own goals and talk to a licensed adviser before acting.)
Quick checklist before buying
-
Strategy fit – does a single-sector ETF suit your diversification plan?
-
Hedged vs un-hedged – outlook for AUD over your holding period.
-
Fee drag – 0.57 % plus hedging cost; total ~1.2 % in a flat year.
-
Re-invest distributions – to capture total return, not just price.
-
Position size & risk limits – healthcare ≈ 12 % of MSCI World; keeping DRUG around that weight avoids concentration risk.
Need a side-by-side sheet comparing DRUG with IXJ (un-hedged) and VHT (global healthcare un-hedged via Vanguard)? Let me know and I can spin up a quick table or tracker.
Wednesday, July 9, 2025
Semiconductor ETF - ASX
If you're seeking exposure to the semiconductor sector through an ETF listed on the ASX, the Global X Semiconductor ETF (ASX) is currently the primary option available.(bestetfs.com.au)
🔹 Global X Semiconductor ETF (ASX:SEMI)
-
Objective: Tracks the Solactive Global Semiconductor 30 Index, providing exposure to 30 of the world's leading semiconductor companies.
-
Top Holdings: Includes major players like Taiwan Semiconductor Manufacturing Company, Broadcom, NVIDIA, ASML, and AMD.
-
Management Fee: 0.45% p.a.
-
Assets Under Management: Approximately A$350 million as of June 2025.
-
Dividend Yield: Around 3.4%, with semi-annual distributions.
-
Performance: Delivered a 1-year return of 6.09% and an average annual return of 19.71% since inception in August 2021.(Listcorp, Stock Analysis, globalxetfs.com.au, InvestSMART)
This ETF offers diversified exposure to the global semiconductor industry, encompassing companies involved in chip design, manufacturing, and related technologies.
🔹 Alternative ASX ETFs with Indirect Semiconductor Exposure
While not exclusively focused on semiconductors, the following ETFs provide indirect exposure through broader technology investments:(globalxetfs.com.au)
-
BetaShares S&P/ASX Australian Technology ETF (ASX:ATEC): Tracks the S&P/ASX All Technology Index, which includes Australian tech companies, some of which may be involved in semiconductor-related activities.
-
BetaShares Global Robotics and Artificial Intelligence ETF (ASX:RBTZ): Invests in global companies involved in robotics and AI, sectors that heavily rely on semiconductor technologies.
-
BetaShares Asia Technology Tigers ETF (ASX:ASIA): Provides exposure to leading Asian technology companies, many of which are significant players in the semiconductor industry.
These ETFs offer broader technology sector exposure, which includes, but is not limited to, semiconductor companies.
Thursday, June 19, 2025
CAGR
Here’s a snapshot of the Compound Annual Growth Rate (CAGR) for major stock markets over the past 10 years, based on index-level performance:
| Market | Approx. 10-Year CAGR | Index Used | Notes |
|---|---|---|---|
| India | ~10.9% | Nifty Large Cap Index | Outperformed peers with strong macro fundamentals and corporate earnings. |
| China | ~2.7% | MSCI China Index | Weighed down by regulatory pressures and slower growth. |
| Australia | ~9.4% | ASX 200 (All Ords TR) | Stable returns with strong dividend yield. |
| USA | ~15% | S&P 500 | Led by tech sector and post-COVID bull run. |
These figures are in local currency terms and reflect index-level returns, not individual stock or fund performance. If you're comparing for investment purposes, I can help factor in currency effects or simulate SIP-style returns across these markets. Want to explore that? 📈🌏
ASX Returns = (CAGR) over the past 30 years
According to long-term data from Vanguard, an investment into a simple, diversified basket of local companies (i.e. Vanguard Australian Shar...